UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Overview of the treatment of disseminated castration-sensitive prostate cancer

Author
Nancy A Dawson, MD
Section Editors
Nicholas Vogelzang, MD
W Robert Lee, MD, MS, MEd
Jerome P Richie, MD, FACS
Deputy Editor
Michael E Ross, MD

INTRODUCTION

Although most cases of prostate cancer are diagnosed and treated while disease is localized, some men have evidence of metastatic prostate cancer at presentation, and others develop disseminated disease after their definitive treatment. This may be manifested by the presence of an elevated serum prostate-specific antigen (PSA) after initial definitive therapy or by the presence of metastases.

Contemporary research has led to the development of multiple active treatment modalities for men with advanced disease. Management of men with advanced prostate cancer involves the sequential use of these and older approaches, with the goals of prolonging survival, minimizing complications, and maintaining quality of life.

The initial approach to treatment for patients with disseminated prostate cancer includes the use of androgen deprivation therapy and is presented here.

Men who relapse after their initial systemic hormonal therapy are considered to have castration-resistant prostate cancer. (See "Overview of the treatment of castration-resistant prostate cancer (CRPC)".)

The initial management of men with localized prostate cancer is discussed separately:

                     

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2017. | This topic last updated: Jul 07, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25:1596.
  2. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on July 06, 2012).
  3. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65:467.
  4. Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368:1314.
  5. Klotz L, O'Callaghan CJ, Ding K. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013 (abstract #3). J Clin Oncol 2011.
  6. Rusthoven CG, Jones BL, Flaig TW, et al. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol 2016; 34:2835.
  7. Löppenberg B, Dalela D, Karabon P, et al. The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis. Eur Urol 2016.
  8. Ost P, Bossi A, Decaestecker K, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 2015; 67:852.